Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
p38 MAP kinase inhibitor |
| gptkbp:ATCCode |
none (not assigned)
|
| gptkbp:CASNumber |
878513-46-9
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:hasMolecularFormula |
C18H16ClF2N3O2
|
| gptkbp:hasSMILES |
CC1=NC(=C(C(=N1)NC2=CC=CC=C2)C3=CC(=C(C=C3)Cl)F)C(=O)N
|
| https://www.w3.org/2000/01/rdf-schema#label |
Losmapimod
|
| gptkbp:intendedUse |
treatment of COVID-19
treatment of inflammatory diseases treatment of muscular dystrophy |
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
inhibits p38 alpha and beta mitogen-activated protein kinases
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
11561616 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea headache |
| gptkbp:status |
investigational
|
| gptkbp:studiedBy |
gptkb:acute_coronary_syndrome
gptkb:facioscapulohumeral_muscular_dystrophy COVID-19 pneumonia |
| gptkbp:synonym |
GW856553X
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:bfsParent |
gptkb:MAPK/p38_pathway
|
| gptkbp:bfsLayer |
7
|